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We report here a case of primary pulmonary epithelioid hemangioendothelioma diagnosed in a 67-year-old Caucasian man,
presenting with exertion dyspnoea, dry cough, and multiple bilateral pulmonary nodules revealed by computed tomography.
At the 18F-ﬂuorodeoxyglucose positron emission tomography, these nodules were negative. The histopathological diagnosis was
made on a pulmonary wedge resection (performed during video-thoracoscopic surgery).
1.Introduction
Pulmonary epithelioid hemangioendothelioma (PEH) is a
rare, low- to intermediate-grade tumor of endothelial origin
[1] with around 120 cases reported in the literature [2]. At
the onset, the patients are usually asymptomatic or present
with nonspeciﬁc symptoms (such as weight loss, fatigue,
dyspnoea, cough, and chest pain). Chest imaging usually
shows the presence of multiple, bilateral small pulmonary
lesions. The diagnosis usually requires a lung biopsy. The
treatment is still not standardized. Surgery is suggested in
presence of a solitary nodule or few unilateral nodules. In-
stead if the lesions are unresectable or multiple and bilateral
several chemotherapy protocols have been used. The prog-
nosis is variable with a median survival of 4-5 years.
2.CaseReport
A 67-year-old Caucasian man, lifelong nonsmoker, with no
prior history of lung diseases, was referred to our university
hospital for the presence, in the last 3 months, of exertion
dyspnoea (grade 1 according to the Medical Research Coun-
cil scale [3]) and dry cough. He had worked as an employee
without occupational exposures of clinical relevance. His
past medical history was characterized by an herniated lum-
bardisc,systemicarterialhypertension(treatedwithcalcium
blockers), diabetes mellitus (treated with oral hypoglycaemic
agents),andpolycythemiavera(diagnosedin2007andtreat-
ed from 2008 with hydroxyurea). Physical examination was
unremarkable. Arterial blood gases analysis performed with
the patient breathing room air demonstrated normal val-
ues (pH 7.40, PaCO2 43mmHg, PaO2 91mmHg, and bicar-
bonate level 26mmoL/L). Routine laboratory tests were
within the normal range except for those listed in Table 1.
Serum levels of neoplastic markers were within normal
range, including carcinoembryonic antigen (2.7ng/mL),
prostate-speciﬁc antigen (3.75ng/mL), and CA19.9 (15U/
mL). Also the serum levels of angiotensin-converting en-
zyme (11 IU/mL) and β2 microglobulin (2.50mg/mL) were
within normal limits.2 Case Reports in Medicine
Table 1: Laboratory tests concerning diabetes mellitus and polycythemia vera.
White blood cells 12.01 × 103 Normal range 4.00–11 × 103/μL
Red blood cells 4.80 × 106 Normal range 4.50–6.50 × 106/μL
HGB 15.9 Normal range 13.0–18 g/dl
HCT 49 Normal range 40–54%
MCV 103 Normal range 76–96 ﬂ
MCH 33.1 Normal range 27.0–32.0 pg/dl
MCHC 32.3 Normal range 30.0–35.0 g/dl
PLT 434 Normal range 150–450 × 103/μL
Blood neutrophils 9.56 × 103 Normal range 2.00–7.50 × 103/μL
Blood lymphocytes 1.92 × 103 Normal range 1.50–5.00 × 103/μL
Blood monocytes 0.43 × 103 Normal range 0.20–1.00 × 103/μL
Blood eosinophils 0.08 × 103 Normal range 0.04–0.40 × 103/μL
Blood basophils 0.01 × 103 /
PT 1.09 Normal range 0.85–1.20 INR
APTT 1.22 Normal range 0.85–1.20 ratio
Glycaemia 99 Normal range 70–11mg/dl
Creatinine 1.2 Normal range 0.9–1.4mg/dl
APTT: Activated thromboplastin time. HCT: Hematocrit. HGB: Haemoglobin. LDH: Lactate dehydrogenase. MCH: Mean corpuscular Haemoglobin. MCV:
M e a nb l o o dc e l lv o l u m e .M C H C :M e a nc e l lh a e m o g l o b i nc o n c e n t r a t i o n .P L T :P l a t e l e t s .P T :P r o t h r o m b i nt i m e .
The pulmonary function tests showed the presence of a
restrictive pattern with a vital capacity (VC) of 3.14 litres
(70% of the predicted value), a forced vital capacity (FVC)
of 3.11 litres (72% of the predicted value), forced expir-
atory volume in one second (FEV1) of 2.55 litres (76.5% of
predicted value), a FEV1/VC ratio of 81% (108% of the pre-
dicted value) and a total lung capacity (TLC), 5.35 litres
(73.3% of the predicted value). DLCO was in the normal
range (Figure 1).
The chest radiography and a computed tomography of
the chest (performed with iodine intravenous contrast me-
dium) showed the presence of multiple bilateral pulmonary
nodules (with a diameter variable between 3mm and 3cm)
without contrast enhancement and the presence of one nod-
ule(withthediameterof2cm)inthefourthhepaticsegment
showing late-phase contrast enhancement and another in
the spleen (with the diameter of 1cm) with cystic features
(Figure 2).
Interestingly, at the 18F-ﬂuorodeoxyglucose positron
emission tomography (PET), all these nodules were not
showing any uptake of the tracer (Figure 3).
The ﬁberoptic bronchoscopy was normal. A transbron-
chial lung biopsy and an ultrasound-guided transthoracic
lung biopsy were both nondiagnostic.
The ﬁnal diagnosis of pulmonary epithelioid heman-
gioendotheliomawasmadebypulmonarywedgeresectionof
anodulelocatedintheleftlowerlobebyvideo-thoracoscopic
surgery. Histopathological examination of the resected tissue
revealed round- to oval-shaped nodules, with a central
sclerotic, hypocellular zone, and peripheral zone rich of cells.
There was tumour diﬀusion into the adjacent bronchioles
and the alveolar spaces with micropolypoid aspects. The ex-
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Figure 1: Flow volume loop.
tracellular stroma consisted of an abundant matrix of chon-
droid, hyaline, mucinous, or myxomatous appearance.
The neoplastic cells were of polygonal shape and eosin-
ophilic with round nuclei and uniform small to moderately
sized nucleoli. Some cells had cytoplasmic vacuoles.
Immunohistochemical studies demonstrated that the
neoplastic cells are endothelial cells immunoreactive for Von
Willebrand factor, CD31, CD34, and vimentin (Figure 4).
Immunostaining for other markers (including caudal
type homeobox transcription factor 2 (CDX2), cytokeratin
(CK) 20, CK7, prostate-speciﬁc antigen (PSA), pan-cytok-
eratin, chromogranin, epithelial membrane antigen (EMA),
HMB45, progesterone receptor, and thyroid transcription
factor (TTF)-1) was negative.Case Reports in Medicine 3
(a) (b)
(c) (d)
Figure 2: The chest radiography (a, b) and a computed tomography of the chest (performed with iodine intravenous contrast medium) (c,
d) showed the presence of multiple bilateral pulmonary nodules.
3. Discussion
Pulmonary epithelioid hemangioendothelioma (PEH) is a
rare, low- to intermediate-grade tumor of endothelial origin
[1].Epithelioidhemangioendotheliomacanarisefrommany
organs, including lungs, liver, bone, and soft tissue, simulta-
neously or sequentially. When this occurs, it may be diﬃcult
to determinate if the tumor is multicentric from the begin-
ning or there is a primary lesion with metastases to the other
tissues [4] .A r o u n d1 2 0c a s e sh a v eb e e nr e p o rt e di nl i t e ra t u r e
[2, Table 2], only ﬁve of them were in Italian patients [5, 15–
18]. Mean (SD) age of patients is 40.1 (17.5) years, and 73%
arefemales[6].Interestingly,ourpatientisinsteada67-year-
old male. Most patients are asymptomatic at presentation,
and some are complaining of weight loss, fatigue, dyspnoea,
fever, pleuritic chest pain, mild nonproductive cough, and
haemoptysis [19]. In most cases, the physical examination
is normal, but few cases of digital clubbing and pleural
eﬀusions have been reported [1, 6].
The most characteristic feature of PEH on chest radio-
graphsorCTisthepresenceofmultipleperivascularnodules
with well- or ill-deﬁned margins in both lungs. The nodules
may range in size up to 2cm, but most of them are ≤1cmin
diameter; they are usually found near medium-sized vessels
and bronchi [1]. This radiological presentation is suggestive
of many lung diseases (Table 3).
Some authors consider 18F-ﬂuorodeoxyglucose positron
emission tomography an important tool for PEH diagnosis
[7];however,inourpatient,thePETwasnegative,suggesting
that a negative PET cannot exclude PEH. Unfortunately, we
do not have a molecular explanation for this ﬁnding but may
be related to a low proliferation rate of the neoplastic cells.
The diagnosis of PEH is made on the basis of the histo-
pathological features and conﬁrmed using immunohisto-
chemicalstainingforendothelialcellmarkers,suchasagainst
factor VIII-related von Willebrand antigen, CD31 or CD34
[2, 4, 13, 20, 21].
The prognosis is variable. The 5-year survival is around
60% (range 47–71%). In fact, there are two groups of PEH
at the clinical presentation: (1) one asymptomatic, with a
solitary pulmonary nodule or unilateral multiple nodules.
Usually they can be managed with surgery alone, and lym-
phatic invasion is unlikely. Their prognosis is good with a
median survival of more than 10 years; (2) another symp-
tomatic group presents with multiple bilateral pulmonary
nodules or pleural eﬀusion with scarce response to chemo-
therapy. The prognosis of this group is poor [11]. Most
patientsdiefrompulmonaryinsuﬃciencyasaresultofanin-
creasing number of tumor nodules [9]. Hematogeneous
metastases are rare and have been described especially in the
liver but also in other sites [2, 4].4 Case Reports in Medicine
Figure 3: 18F-ﬂuorodeoxyglucose positron emission tomography, all these nodules were not showing any uptake of the tracer.
Table 2: Review of the clinical, radiological and pathological features of the published cases of primary pulmonary epithelioid heman-
gioendothelioma.
Review of the literature Our case report
Female/male ratio 3:1 female Male
Mean (SD) age 40.1 (17.5) years 67 years
Symptoms
Weight loss, fatigue, and respiratory symptoms
(dyspnoea, chest pain, mild nonproductive
cough, and mild haemoptysis)
Dyspnoea and dry cough
Chest radiography and
computed tomography Usually multiple bilateral pulmonary nodules Multiple bilateral pulmonary nodules
PET Positive Negative
Metastatic sites
Lymph nodes, liver, bone, skin, serosal
membranes, spleen, tonsils, retroperitoneum,
kidney and central nervous system
Single spleen and liver metastatic nodules
Immunohistochemical
features
Factor VIII von Willebrand factor+, CD31+, or
CD34+
Factor VIII von Willebrand factor+, CD31+,
CD34+
5-year survival (%) 60% Alive for eight months then lost at the follow up
Obtained with the data from [4–18].Case Reports in Medicine 5
(a) (b)
(c) (d)
Figure 4: (a) Neoplastic nodule showing increased number of cells at the periphery with an eosinophilic stroma (H/E, 100x magniﬁcation).
(b) The neoplastic cells are of polygonal shape and eosinophilic with round nuclei and uniform small to moderately sized nucleoli.
(H/E, 200x magniﬁcation). (c) Immunoperoxidase staining for CD34 of the neoplastic cells (brown colour) (200x magniﬁcation). (d)
Immunoperoxidase staining for CD31 of the neoplastic cells (brown colour) (200x magniﬁcation).
Table 3: Diﬀerential diagnosis of multiple pulmonary bilateral
nodules.
Metastases
Primary lung cancer (particularly bronchioloalveolar carcinoma)
Lymphoid tumors and myeloma
Leukaemic inﬁltrates
Benign vascular tumors (hemangioma and lymphangioma)
Malignantvasculartumors(angiosarcomaandKaposi’ssarcoma)
Neuroendocrine tumourlets
Nodular lesions in pulmonary ﬁbrosis
Pneumoconiosis
Infections (tuberculosis, nocardiosis, aspergillosis, and histop-
lasmosis)
Sarcoidosis
Langerhan’s cell histiocytosis
Vasculitis
Connectivitis
Pulmonary arteriovenous malformations
Obtained with the data from [4, 5, 9, 12–14].
The treatment of PEH is not standardized. Surgery alone
is indicated in the presence of a single pulmonary nodule or
unilateral multiple nodules. Lung transplantation should be
considered in patients with vascular inﬁltration [10].
Various chemotherapies have been reported for unre-
sectable or metastatic PEH, with variable eﬀectiveness [22].
Otherauthorshavesuggestedaroleforthehormonaltherapy
(antiestrogens and progesterone) in patients with diﬀuse dis-
ease if the neoplastic cells express estrogen and progesterone
receptors [23]. A slight regression of the pulmonary lesions
was also obtained with interferon (IFN)-2α,p r o b a b l yf o ri t s
antiangiogenic activity [24]. Thalidomide and IFN-α have
also been proposed for unresectable cases [22]. Some bene-
ﬁcial results were also obtained with bevacizumab, a mon-
oclonal antibody that blocks human VEGF-A [22, 25]. The
neoplastic cells express glucocorticoid receptors and the en-
zyme11β-hydroxysteroiddehydrogenaseinvolvedinthesyn-
thesis of the steroids, suggesting a potential role for steroid
modulators [26].
In conclusion, we had the opportunity to observe an un-
usual primary pulmonary hemangioepithelioma in an old6 Case Reports in Medicine
male patient, and interestingly, in comparison with the pub-
lished literature, the neoplastic lesions were PET negative.
Again, as previously suggested [27], we stress the importance
of starting an international clinical registry of this unusual
neoplasm.
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